PMID- 30641912
OWN - NLM
STAT- MEDLINE
DCOM- 20190501
LR  - 20200225
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 20
IP  - 2
DP  - 2019 Jan 11
TI  - CMV-Specific Immune Response-New Patients, New Insight: Central Role of Specific 
      IgG during Infancy and Long-Lasting Immune Deficiency after Allogenic Stem Cell 
      Transplantation.
LID - 10.3390/ijms20020271 [doi]
LID - 271
AB  - Although the existing paradigm states that cytomegalovirus (CMV) reactivation is 
      under the control of the cellular immune response, the role of humoral and innate 
      counterparts are underestimated. The study analyzed the host(-)virus interaction 
      i.e., CMV-immune response evolution during infection in three different clinical 
      situations: (1) immunodeficient CMV-positive human leukocyte antigen 
      (HLA)-matched bone marrow recipients after immunoablative conditioning as well as 
      immunocompetent, (2) adult, and (3) infant with primary immune response. In the 
      first situation, a fast and significant decrease of specific immunity was 
      observed but reconstitution of marrow-derived B and natural killer (NK) cells was 
      observed prior to thymic origin of T cells. The lowest CMV-IgG (93.2 RU/mL) was 
      found just before CMV viremia. It is noteworthy that the sole and exclusive 
      factor of CMV-specific immune response is a residual recipient antibody class 
      IgG. The CMV-quantiferon increase was detected later, but in the first phase, 
      phytohemagglutinin (PHA)-induced IFN-gamma release was significantly lower than that 
      of CMV-induced ("indeterminate" results). It corresponds with the increase of NK 
      cells at the top of lymphocyte reconstitution and undetected CMV-specific CD8 
      cells using a pentamer technique. In immunocompetent adult (CMV-negative donor), 
      the cellular and humoral immune response increased in a parallel manner, but 
      symptoms of CMV mononucleosis persisted until the increase of specific IgG. 
      During infancy, the decrease of the maternal CMV-IgG level to 89.08 RU/mL 
      followed by clinical sequel, i.e., CMV replication, were described. My 
      observations shed light on a unique host-CMV interaction and CMV-IgG role: they 
      indicate that its significant decrease predicts CMV replication. Before primary 
      cellular immune response development, the high level of residual CMV-IgG (about 
      >100 R/mL) from mother or recipient prevents virus reactivation. The innate 
      immune response and NK-dependent IFN-secretion should be further investigated.
FAU - Zdziarski, Przemyslaw
AU  - Zdziarski P
AUID- ORCID: 0000-0002-5692-4734
AD  - Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of 
      Sciences, 53-114 Wroclaw, Poland. zdziarski@oil.org.pl.
AD  - Department of Clinical Immunology and Hospital Infection Control Team, Lower 
      Silesian Center for Cellular Transplantation, 53-439 Wroclaw, Poland. 
      zdziarski@oil.org.pl.
AD  - Military Institute WITI Wroclaw; 136 Obornicka Str., 50-961 Wroclaw, Poland. 
      zdziarski@oil.org.pl.
LA  - eng
GR  - 2014/2018/Leading National Research Centre (KNOW) Wroclaw Centre of 
      Biotechnology/
PT  - Journal Article
DEP - 20190111
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Antibodies, Viral)
RN  - 0 (Immunoglobulin G)
SB  - IM
MH  - Antibodies, Viral/metabolism
MH  - B-Lymphocytes/metabolism
MH  - Cytomegalovirus/*immunology
MH  - Cytomegalovirus Infections/*immunology
MH  - Female
MH  - Hematopoietic Stem Cell Transplantation/*adverse effects
MH  - Humans
MH  - Immunity, Cellular
MH  - Immunity, Humoral
MH  - *Immunocompetence
MH  - *Immunocompromised Host
MH  - Immunoglobulin G/*metabolism
MH  - Infant
MH  - Killer Cells, Natural/metabolism
MH  - Male
MH  - Middle Aged
PMC - PMC6358762
OTO - NOTNLM
OT  - CMV-specific IgG
OT  - QuantiFERON
OT  - adoptive/acquired, innate immune response
OT  - cytomegalovirus (CMV)
OT  - epidemiology
OT  - epitope engineering
OT  - hematopoietic stem cell transplantation (HSCT)
OT  - host-virus interaction
OT  - natural killer (NK) cells
OT  - pentamer
OT  - protective IgG level
OT  - secondary immunodeficiency
OT  - beta2-microglobulin
COIS- The author declares no conflict of interest.
EDAT- 2019/01/16 06:00
MHDA- 2019/05/02 06:00
PMCR- 2019/01/01
CRDT- 2019/01/16 06:00
PHST- 2018/12/19 00:00 [received]
PHST- 2019/01/02 00:00 [revised]
PHST- 2019/01/03 00:00 [accepted]
PHST- 2019/01/16 06:00 [entrez]
PHST- 2019/01/16 06:00 [pubmed]
PHST- 2019/05/02 06:00 [medline]
PHST- 2019/01/01 00:00 [pmc-release]
AID - ijms20020271 [pii]
AID - ijms-20-00271 [pii]
AID - 10.3390/ijms20020271 [doi]
PST - epublish
SO  - Int J Mol Sci. 2019 Jan 11;20(2):271. doi: 10.3390/ijms20020271.